AQST 240816 3.50C (AQST240816C3500) Stock Options, News & Quotes

US OptionsDetailed Quotes

AQST240816C3500

Watchlist

0.70
+0.35+100.00%

15min DelayClose Aug 16 15:59 ET

0.75High0.55Low

Intraday

5D
Daily

News

Express News | Aquestive Therapeutics Reiterates Expected Timing For Anaphylm NDA Filing For Q1 2025
BenzingaAug 14 08:08 ET
Express News | Aquestive Therapeutics : Reiterates Expected Timing for Filing Nda for Anaphylm Sublingual Film to FDA in Q1 of 2025
ReutersAug 14 08:00 ET
Express News | Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for Nda Filing of Anaphylm™
ReutersAug 14 08:00 ET
Buy Rating Affirmed for Aquestive Therapeutics as Anaphylm Poised to Transform Epinephrine Market
TipRanksAug 14 06:38 ET · Ratings
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Moomoo NewsAug 14 06:34 ET · Ratings
Raymond James Ups ARS to Strong Buy, Cites FDA Neffy Approval
Seeking AlphaAug 13 12:26 ET

Comments

Jaguar8

Aug 14 12:08

NEWS

$Aquestive Therapeutics (AQST.US)$
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
Aquestive Therapeutics (NASDAQ: AQST) has commented on the FDA's recent approval of the first non-injection-based epinephrine device for treating severe allergic reactions, including anaphylaxis. The company views this as a positive development for patients seeking altern...

Jaguar8

Aug 6 15:23

NEWS

$Aquestive Therapeutics (AQST.US)$
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Aquestive Therapeutics (NASDAQ:AQST) reported its Q2 2024 financial results and shared business updates. Key highlights include:
Anaphylm™ (epinephrine) Sublingual Film remains on track for FDA submission in early 2025, with a potential launch by late 2025 or early 2026.
Positive topline pharmacokinetic (PK) and pharmacodynamic (PD) data reported, showing no ...

TrendTrader

Jul 26 09:52

Looking for 4

$Aquestive Therapeutics (AQST.US)$

Trytosaveabit

Jul 25 07:01

Update

$Aquestive Therapeutics (AQST.US)$ Aquestive Therapeutics Inc: Meets Primary Study Endpoints

Jaguar8

May 7 15:23

$Aquestive Therapeutics (AQST.US)$
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...